Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research
- 1 September 2013
- journal article
- Published by Elsevier in Value in Health
- Vol. 16 (6), 1054-1062
- https://doi.org/10.1016/j.jval.2013.05.008
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Implementing the Learning Health System: From Concept to ActionAnnals of Internal Medicine, 2012
- Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2012
- Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug DevelopmentClinical Pharmacology & Therapeutics, 2011
- Availability of Comparative Efficacy Data at the Time of Drug Approval in the United StatesPublished by American Medical Association (AMA) ,2011
- Age, Exclusion Criteria, and Generalizability of Randomized Trials Enrolling Kidney Transplant RecipientsTransplantation, 2011
- How Many “Me-Too” Drugs Is Too Many?Published by American Medical Association (AMA) ,2011
- In Defense of Pharmacoepidemiology — Embracing the Yin and Yang of Drug ResearchNew England Journal of Medicine, 2007
- Developments in Post-marketing Comparative Effectiveness ResearchClinical Pharmacology & Therapeutics, 2007
- External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?Thorax, 2007
- A review of uses of health care utilization databases for epidemiologic research on therapeuticsJournal of Clinical Epidemiology, 2005